Booming Alzheimer’s Therapeutics Market Projected to Reach US$7,359.7 Million by 2033, Fueled by 9.2% CAGR | FMI Report

Alzheimer’s Therapeutics Market

The worldwide market for Alzheimer’s Therapeutics is poised to achieve a worth of US$ 3,052.3 million in 2023. Anticipated growth in demand for Alzheimer’s therapeutics indicates a projected Compound Annual Growth Rate (CAGR) of 9.2%, driving the market to attain a value of US$ 7,359.7 million by 2033.

The mortality rates due to Alzheimer’s Therapeutics are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased by 14%, 23% and 11%, respectively, while deaths from ALZHEIMER’S THERAPEUTICS increased by 71% in the U.S. Similarly, According to Alzheimer’s Therapeutics International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increase in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Get your hands on a visually captivating sample report featuring related graphs and charts. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-14497

Population ageing across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in the number of the aged population. In addition, is associated with an increased prevalence of chronic diseases like dementia.

Therapies for Alzheimer’s therapeutics offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease Alzheimer’s Therapeutics cement. Thus, the magnitude of the affected population and the lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers.

However, the identification of the primary reasons and mechanisms involved in Alzheimer’s therapeutics is limited. Drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations. One of the significant trends observed in this market is the collaboration of the existing players.

Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates, which is further expected to propel the demand.

Developing countries are expected to offer lucrative opportunities for this market. According to Alzheimer’s Therapeutics International in 2015, 58% of people with dementia live in developing countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific region.

According to World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, however, all other regional estimates fall in a relatively between 5.6% and 7.6%.

Discover the power of methodology-driven insights today. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14497

A list of Key Players Covered in the Alzheimer’s Therapeutics Market are:

  • AbbVie, Inc.
  • Teva Pharmaceuticals Ltd.
  • Eisai Co., Ltd.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Novartis AG
  • Zydus Lifesciences Ltd (CADILA)
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals Inc.
  • Macleods Pharmaceuticals Ltd.
  • Viatris Inc.
  • Lupin Ltd
  • Cipla Ltd.
  • Torrent pharmaceuticals ltd.
  • Unichem laboratories ltd
  • Lannett Inc.

Key Market Segments Covered in Alzheimer’s Therapeutics Industry Research

By Drug Name:

  • Donepezil
  • Rivastigmine
  • Memantine
  • Galantamine
  • Manufactured a combination of memantine and donepezil

By Drug Class:

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Manufactured Combination

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogsYouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these